Granted Patent
B2
US 12,251,449 · App. 17/127,512 · Granted Mar 18, 2025
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
Inventors:
Jeffrey Hartgerink (Pearland, TX); Andrew G. Sikora (Houston, TX); David Leach (Houston, TX); Jared M. Newton (Houston, TX); Simon Young (Houston, TX)
Assignees:
William Marsh Rice University; Baylor College of Medicine; The Board of Regents of The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are compositions comprising multi domain peptide (MDP) hydrogels where the peptides that constitute the hydrogel have at least one N6-(1-iminoethyl)-lysine side chain. Also provided are hydrogels that further comprise a STING agonist, an immune checkpoint inhibitor, and/or an anti-cancer therapy. Also provided are methods of using such compositions in the treatment of cancer.
Claims (10)
1. A peptide comprising a first domain, a second domain, and a third domain; wherein the first and third domain are each X m and m is 1-3; wherein the first domain is positioned at the N-terminal end of the second domain; wherein the third domain is positioned at the C-terminal end of the second domain; wherein the second domain comprises (SerLeu) 6 ; and wherein X is an amino acid having a side chain of N6-(1-iminoethyl)-lysine (L-NIL).
2. The peptide of claim 1 , wherein the peptide is N-terminally acetylated.
3. The peptide of claim 1 , wherein the peptide is C-terminally amidated.
4. A hydrogel comprising a plurality of peptides according to claim 1 .
5. The hydrogel of claim 4 , wherein the hydrogel is biocompatible.
6. The hydrogel of claim 4 , wherein the hydrogel remains intact at pH 3-11.
7. The hydrogel of claim 4 , wherein the hydrogel remains intact at physiological pH.
8. The hydrogel of claim 4 , further comprising a cyclic dinucleotide (CDN), an immune checkpoint inhibitor, and/or an anti-cancer drug.
9. The hydrogel of claim 4 , wherein the CDN is dithio-(R P ,R P )-[cyclic[A(2′,5′)pA(3′,5′)p]], 2′2′-cGAMP, 2′3′-cGAMP, 3′3′-cGAMP, c-di-AMP, 2′3′-c-di-AMP, 2′3′-c-di-AM(PS)2, c-di-GMP, c-di-UMP, or c-di-IMP.
10. The hydrogel of claim 8 , wherein the immune checkpoint inhibitor is a PD-L1 antibody, a PD-1 antibody, or a CTLA4 antibody.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 31, 2025
From: YOUNG, SIMON
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 070069/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 30, 2025
From: HARTGERINK, JEFFREY; LEACH, DAVID
To: WILLIAM MARSH RICE UNIVERSITY
Reel/Frame 070067/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 30, 2025
From: SIKORA, ANDREW G.; NEWTON, JARED M.
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 070067/0328 →
Continuity (2)
Provisional Application
62950718
· Dec 19, 2019
References Cited (116)
US 7569555B2
· Karaolis
· 2009
[cited by applicant]
US 7592326B2
· Karaolis
· 2009
[cited by applicant]
US 7709458B2
· Karaolis et al.
· 2010
[cited by applicant]
US 9226959B2
· Kramps et al.
· 2016
[cited by applicant]
US 9526762B1
· Hartgerink et al.
· 2016
[cited by applicant]
US 20050272662A1
· Stupp et al.
· 2005
[cited by applicant]
US 20140135472A1
· King et al.
· 2014
[cited by applicant]
US 20160287623A1
· Gajewski et al.
· 2016
[cited by applicant]
US 20170172953A1
· Hartgerink et al.
· 2017
[cited by applicant]
US 20180354991A1
· Wilson
· 2018
[cited by examiner]
US 20230143731A1
· Kibbe
· 2023
[cited by examiner]
WO WO2013185052
· 2013
[cited by applicant]
WO WO2014093936
· 2014
[cited by applicant]
WO WO2014104981
· 2014
[cited by applicant]
WO WO2015016718
· 2015
[cited by applicant]
WO WO2015185565
· 2015
[cited by applicant]
WO WO2016096577
· 2016
[cited by applicant]
WO WO2018045058
· 2018
[cited by applicant]
WO WO2019018572
· 2019
[cited by applicant]
WO WO2020081717
· 2020
[cited by applicant]
Leach et al.“Drug-Mimicking Nanofibrous Peptide Hydrogel for Inhibition of Inducible Nitric Oxide Synthase” (ACT Biomater Sci Eng 2019 vol. 5, pp. 6755-6765; published Nov. 13, 2019). (Year: 2019).
[cited by examiner]
The Leach Dissertation, Rice University, Houston, Texas, May 2020. (Year: 2020).
[cited by examiner]
The Lopez-Silva Dissertation, Rice University, Houston, Texas, May 2020. (Year: 2020).
[cited by examiner]
Leach et al.“Biomaterial-Facilitated Immunotherapy for Established Oral Cancers” (ACT Biomater Sci Eng 2021 vol. 7, pp. 415-421; published Jan. 20, 2021). (Year: 2021).
[cited by examiner]
Ablasser et al., “cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING,” Nature, 498(7454):380-384, 2013.
[cited by applicant]
Aduro Biotech, NCT02675439: Feb. 5, 2016 ed.; National Institutes of Health: ClinicalTrails.gov, 2017.
[cited by applicant]
Ahsan, “3-Nitrotyrosine: A biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions,” Human Immunology, 74:1392-1399, 2013.
[cited by applicant]
Aldridge et al., “Lipopolysaccharide-stimulated RAW 264.7 macrophage inducible nitric oxide synthase and nitric oxide production is decreased by an omega-3 fatty acid lipid emulsion,” J. Surg. Res., 149:296-302, 2008.
[cited by applicant]
Ambs et al., “p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells,” Nature Medicine, 4:1371, 1998.
[cited by applicant]
Aulisa et al., “Self-assembly of multidomain peptides: sequence variation allows control over cross-linking and viscoelasticity,” Biomacromolecules, 10:2694-2698, 2009.
[cited by applicant]
Bakota et al., “Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome,” Biomacromolecules. American Chemical Society, 12(5):1651-1657, 2011.
[cited by applicant]
Barber, “STING: infection, inflammation and cancer,” Nat Rev Immunol, 15 (12):760-770, 2015.
[cited by applicant]
Berzofsky et al., “Progress on new vaccine strategies for the immunotherapy and prevention of cancer,” The Journal of Clinical Investigation, 113:1515-1525, 2004.
[cited by applicant]
Bonomi et al., “The Role of Inflammation in Head and Neck Cancer.” In Inflammation and Cancer, Aggarwal, B. B.; Sung, B.; Gupta, S. C., Eds. Springer Basel: Basel, 2014; pp. 107-127.
[cited by applicant]
Bookstaver et al., “Improving Vaccine and Immunotherapy Design Using Biomaterials,” Trends in Immunology, 39:135-150, 2018.
[cited by applicant]
Brudno et al., “Replenishable drug depot to combat post-resection cancer recurrence,” Biomaterials, 178:373-382, 2018.
[cited by applicant]
Bryan & Grisham, “Methods to detect nitric oxide and its metabolites in biological samples,” Free Radical Biology and Medicine, 43:645-657, 2007.
[cited by applicant]
Carrejo et al., “Multidomain peptide hydrogel accelerates healing of full-thickness wounds in diabetic mice,” ACS Biomater. Sci. Eng., 4:1387-1396, 2018.
[cited by applicant]
Chen & Mellman, “Oncology Meets Immunology: The Cancer-Immunity Cycle,” Immunity, 39:1-10, 2013.
[cited by applicant]
Collier & Segura, “Evolving the use of peptides as components of biomaterials,” Biomaterials, 32:4198-4204, 2011.
[cited by applicant]
Corrales et al., “Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity,” Cell Rep., 11(7):1018-1030, 2015.
[cited by applicant]
Cui et al., “Self-assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials,” Peptide Science, 94:1-18, 2010.
[cited by applicant]
Dellacherie et al., “Macroscale biomaterials strategies for local immunomodulation,” Nature Reviews Materials, 4:379-397, 2019.
[cited by applicant]
Deshpande et al., “Nitric oxide modulators: An emerging class of medicinal agents,” Indian J. Pharm. Sci., 74:487-497, 2012.
[cited by applicant]
Dong et al., “Self-Assembly of Multidomain Peptides: Balancing Molecular Frustration Controls Conformation and Nanostructure,” Journal of the American Chemical Society, 129:12468-12472, 2007.
[cited by applicant]
Downey et al., “DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2'3'-cGAMP, Induces M2 Macrophage Repol…
[cited by applicant]
Fukumura et al., “Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability,” Proceedings of the National Academy of Sciences, 98:2604-260…
[cited by applicant]
Fukumura et al., “The role of nitric oxide in tumour progression,” Nature Reviews Cancer, 6:521, 2006.
[cited by applicant]
Gadkaree et al., “Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model,” Head and Neck, 39(6):1086-1094, 20…
[cited by applicant]
Galler et al., “A customized self-assembling peptide hydrogel for dental pulp tissue engineering,” Tissue engineering Part A, 18(1-2):176-184, 2012.
[cited by applicant]
Galler et al., “Self-assembling multidomain peptide hydrogels: designed susceptibility to enzymatic cleavage allows enhanced cell migration and spreading,” J Am Chem Soc., 132(9):3217-3223, 2010.
[cited by applicant]
Galler, “Self-Assembling Peptide Hydrogels Targeted for Dental Tissue Regeneration,” PhD Dissertation, Rice University, UMI No. 342141, 2010.
[cited by applicant]
Grimm et al., “Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target,” Clin. Cancer Res., 19:5557, 2013.
[cited by applicant]
Gu & Mooney, “Biomaterials and emerging anticancer therapeutics: engineering the microenvironment,” Nat. Rev. Cancer, 16:56-66, 2016.
[cited by applicant]
Hanahan & Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell, 144:646-674, 2011.
[cited by applicant]
Hanoteau et al., “Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy,” Journal for ImmunoTherapy of Cancer, 7:10, 2019.
[cited by applicant]
Hanson et al., “Nanoparticle STING agonists are potent lymph node-targeted vaccine adjuvants,” Clin Invest., 125(6):2532-2546, 2015.
[cited by applicant]
Housman et al., “Drug resistance in cancer: an overview,” Cancers, 6:1769-1792, 2014.
[cited by applicant]
Ischiropoulos, “Biological selectivity and functional aspects of protein tyrosine nitration,” Biochemical and Biophysical Research Communications, 305:776-783, 2003.
[cited by applicant]
Ishikawa et al., “STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity,” Nature, 461:788-792, 2009.
[cited by applicant]
Jayaraman et al., “iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity,” Clinical Cancer Research, 20:6439-6451, 20…
[cited by applicant]
Jayaraman et al., “Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release,” The Journal of Immu…
[cited by applicant]
Jenkins et al., “Roles of nitric oxide in tumor growth,” Proceedings of the National Academy of Sciences, 92:4392-4396, 1995.
[cited by applicant]
Judd et al., “Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer,” Otolaryng. Head Neck, 147:493-500, 2012.
[cited by applicant]
Karaolis et al., “3′,5′-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation,” Biochem Biophys Res Commun., 329(1):40-45, 2005.
[cited by applicant]
Kearney & Mooney, “Macroscale delivery systems for molecular and cellular payloads,” Nat. Mater., 12:1004, 2013.
[cited by applicant]
Kim et al., “Enhancement of neuronal cell adhesion by covalent binding of poly-d-lysine,” Journal of Neuroscience Methods, 202:38-44, 2011.
[cited by applicant]
Koshy et al., “Biomaterials for Enhancing Anti-Cancer Immunity,” Current Opinions Biotechnology, 40:1-8, 2016.
[cited by applicant]
Kumar et al., “Drug-triggered and cross-linked self-assembling nanofibrous hydrogels,” Journal of the American Chemical Society, 137:4823-4830, 2015.
[cited by applicant]
Kumar et al., “Highly angiogenic peptide nanofibers,” ACS Nano, 9(1):860-868, 2015.
[cited by applicant]
Kumar et al., “Treatment of hind limb ischemia using angiogenic peptide nanofibers,” Biomaterials, 98:113-119, 2016.
[cited by applicant]
Lam et al., “Cationic surface charge combined with either vitronectin or laminin dictates the evolution of human embryonic stem cells/microcarrier aggregates and cell growth in agitated cultures,” Stem Cells Dev, 23:168…
[cited by applicant]
Leach et al., “STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy,” Biomaterials, 163:67-75, 2018.
[cited by applicant]
Leach et al., “Advances in immunotherapy delivery from implantable and injectable biomaterials,” Acta Biomaterialia, 88:15-31, 2019.
[cited by applicant]
Leach et al., “Drug-Mimicking Nanofibrous Peptide Hydrogel for Inhibition of Inducible Nitric Oxide Synthase,” ACS Biomater. Sci. Eng., 5:6755-6765, 2019.
[cited by applicant]
Leach et al., “Biomaterial-facilitated Immunotherapy for Established Oral Cancers,” ACS Biomateri. Sci. Eng., 7:415-421, 2021.
[cited by applicant]
Lei et al., “MAVS-mediated apoptosis and its inhibition by viral proteins,” PLoS One, 4(5):e5466, 2009.
[cited by applicant]
Li et al., “‘Missing Tooth’ Multidomain Peptide Nanofibers for Delivery of Small Molecule Drugs,” Biomacromolecules, 17:2087-2095, 2016.
[cited by applicant]
Li & Hartgerink, “Covalent Capture of Aligned Self-Assembling Nanofibers,” Journal of the American Chemical Society, 139:8044-8050, 2017.
[cited by applicant]
Lopez-Silva et al., “Self-Assembling Multidomain Peptides: Design and Characterization of Neutral Peptide-Based Materials with pH and Ionic Strength Independent Self-Assembly,” ACS Biomater. Sci. Eng., 5:977-985, 2019.
[cited by applicant]
Lopez-Silva et al., “Chemical functionality of multidomain peptide hydrogels governs early host immune response,” Biomaterials, 231:119667, 2020.
[cited by applicant]
Lu et al., “Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization,” Nat. Commun., 6:6676, 2015.
[cited by applicant]
MacMicking et al., “Nitric Oxide and Macrophage Function,” Annual Review of Immunology, 15:323-350, 1997.
[cited by applicant]
Mannick et al., “S-Nitrosylation of mitochondrial caspases,” The Journal of Cell Biology, 154:1111-1116, 2001.
[cited by applicant]
Miyabe et al., “A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy,” Journal of Controlled Release, 184:20-27, 2014.
[cited by applicant]
Moore et al., “Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers,” Cancer Immunol Res., 4(7):611-620, 2016.
[cited by applicant]
Moore et al., “L-N6-(1-Iminoethyl)lysine: A Selective Inhibitor of Inducible Nitric Oxide Synthase,” J. Med. Chem., 37:3886-8, 1994.
[cited by applicant]
Moore et al., “Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade,” Cancer Immunol Res, 4:1061-1071, 2016.
[cited by applicant]
Moore et al., “Nanofibrous peptide hydrogel elicits angiogenesis and neurogenesis without drugs, proteins, or cells,” Biomaterials, 161:154-163, 2018.
[cited by applicant]
Moore & Hartgerink, “Self-Assembling Multidomain Peptide Nanofibers for Delivery of Bioactive Molecules and Tissue Regeneration,” Accounts of Chemical Research, 50:714-722, 2017.
[cited by applicant]
Moy et al., “Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma,” Eur. J. Cancer, 76:152-166, 2017.
[cited by applicant]
Nathan & Hibbs, “Role of nitric oxide synthesis in macrophage antimicrobial activity,” Current Opinion in Immunology, 3:65-70, 1991.
[cited by applicant]
Newton et al., “Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition,” J. Immunother. Cancer, 7:216, 2019.
[cited by applicant]
Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nat Rev Cancer, 12(4):252-264, 2012.
[cited by applicant]
Park et al., “Extended Release of Perioperative Immunotherapy Prevents Tumor Recurrence and Eliminates Metastases,” Sci Transl Med., 10(433), 2018.
[cited by applicant]
Romling et al., “Cyclic di-GMP as a second messenger,” Curr Opin Microbiol., 9(2):218-228, 2006.
[cited by applicant]
Samadi et al., “A multi-targeted approach to suppress tumor-promoting inflammation,” Seminars in Cancer Biology, 35:S151-S184, 2015.
[cited by applicant]
Schneider et al., “The effect of hydrogel charge density on cell attachment,” Biomaterials, 25:3023-3028, 2004.
[cited by applicant]
Sikora et al., “Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy,” Clinical Cancer Research, 16:1834, 2010.
[cited by applicant]
Sun et al., “Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy,” JCI Insight, 4:e126853, 2019.
[cited by applicant]
Tamura et al., “The IRF Family Transcription Factors in Immunity and Oncogenesis,” Annu Rev Immunol, 26 (1):535-584, 2008.
[cited by applicant]
Tang et al., “Mechanistic studies of inactivation of inducible nitric oxide synthase by amidines,” Biochemistry, 54:2530-2538, 2015.
[cited by applicant]
Wang & Mooney, “Biomaterial-assisted targeted modulation of immune cells in cancer treatment,” Nature Materials, 17:761-772, 2018.
[cited by applicant]
Wang et al., “Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management,” Frontiers in Pharmacology, 10:1254, 2019.
[cited by applicant]
Wickremasinghe et al., “Two-Step Self-Assembly of Liposome-Multidomain Peptide Nanofiber Hydrogel for Time-Controlled Release,” Biomacromolecules, 15:3587-3595, 2014.
[cited by applicant]
Wickremasinghe et al., “Controlled Angiogenesis in Peptide Nanofiber Composite Hydrogels,” ACS Biomater. Sci. Eng. American Chemical Society, 1(9):845-854, 2015.
[cited by applicant]
Xing et al., “Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis,” J. Immunother. Cancer, …
[cited by applicant]
Yamaguchi et al., “Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model,” British Journal of Neurosurgery, 16:567-572, 2002.
[cited by applicant]
Yildiz et al., “Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG,” Eur J Immunol., 45(4):1170-1179, 2015.
[cited by applicant]
Zhang & Xu, “Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes,” Melanoma Research, 11:559-567, 2001.
[cited by applicant]